CC 90001

Drug Profile

CC 90001

Alternative Names: CC90001

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celgene Corporation
  • Class Anti-inflammatories; Antifibrotics
  • Mechanism of Action Mitogen-activated protein kinase 8 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis
  • Discontinued Hepatic fibrosis

Most Recent Events

  • 04 Dec 2017 Celgene plans a phase I trial in Healthy volunteers in USA (NCT03363815)
  • 20 Nov 2017 Discontinued - Phase-I for Hepatic fibrosis (In volunteers) in USA (PO) (Celgene Pipeline, November 2017)
  • 20 Nov 2017 Updated efficacy and adverse event data from a phase I trial in Idiopathic pulmonary fibrosis presented at the 27th Annual Congress of the European Respiratory Society (ERS-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top